NCT07494214 Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants
| NCT ID | NCT07494214 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Healhty |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-03-09 |
| Primary Completion | 2027-03-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2026-03-09 with a primary completion date of 2027-03-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates whether MDMA may have a pain-reducing effect. The effect of MDMA is compared with a placebo (a substance with no active effect). In the study, moderate pain will be artificially created in healthy participants using repeated small electrical pulses applied under the skin. At the same time, participants will take MDMA or a placebo by mouth. This allows researchers to compare how MDMA affects the artificially created pain. A total of 20 healthy volunteers will take part in this study.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 75 years old 2. Sufficient understanding of the German language 3. Understanding of procedures and risks associated with the study 4. Willing to adhere to the protocol and signing of the consent form 5. Willing to refrain from the consumption of illicit psychoactive substances during the study 6. Willing not to operate heavy machinery for 48 hours after the study session. 7. Willing to use effective birth control throughout study participation 8. Body mass index between 18-34.9 kg/m2 Exclusion Criteria: 1. Relevant chronic or acute medical condition 2. Any implanted medical devices (e.g., pacemakers, neurostimulators, or metal prostheses) 3. Current or previous major psychiatric disorder (e.g. bipolar disorder, schizophrenia), current depression or anxiety disorder. 4. Psychotic disorder or bipolar disorder in first-degree relatives 5. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 6. Lifetime use of MDMA on more than 20 occasions or any use within the previous two months 7. Pregnancy or current breastfeeding 8. Participation in another clinical trial (currently or within the last 30 days) 9. Use of medication that may interfere with the effects of the study medication 10. Tobacco smoking (\>10 cigarettes/day) 11. Consumption of alcoholic beverages (\>15 drinks/week)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07494214 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Healhty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07494214 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07494214 currently recruiting?
Yes, NCT07494214 is actively recruiting participants. Contact the research team at severinbenjamin.vogt@usb.ch for enrollment information.
Where is the NCT07494214 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT07494214 clinical trial?
NCT07494214 is sponsored by University Hospital, Basel, Switzerland. The trial plans to enroll 20 participants.